Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Methods The efficacy...

Full description

Bibliographic Details
Main Authors: Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng, Jianyong Li
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Journal of Hematology & Oncology
Subjects:
Bruton’s tyrosine kinase
Chronic lymphocytic leukemia
Relapsed/refractory
Zanubrutinib
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13045-020-00884-4

Internet

http://link.springer.com/article/10.1186/s13045-020-00884-4

Similar Items